Scottsdale Research Institute plans landmark controlled trial of whole psilocybin mushrooms for PTSD

Whole psilocybin mushrooms are set to be tested for PTSD in a controlled study led by the Scottsdale Research Institute (SRI). The effort builds on evidence that psilocybin may help treat PTSD, but focuses on whole mushrooms rather than synthetic, lab-made psilocybin. SRI president Sue Sisley says whole mushrooms may provide an “entourage effect” because they include additional components beyond psilocybin, potentially leading to deeper and longer-lasting results. The institute expects this to be the world’s first controlled trial using whole mushrooms. The study is planned to start in December and enroll 24 subjects split across police officers, firefighters, and military veterans. Participants will receive 4.32 grams of whole mushrooms in chocolate containing 30 mg of psilocybin, use eyeshades and tailored playlists during sessions, and the trial is designed to run for 30 days with longer-term monitoring. SRI also aims to pursue future access under the federal Right To Try Act and is awaiting final DEA approval.